NCT07459998 2026-03-10
SKB103 for Injection in Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1/2 Not yet recruiting
Clinical Trials
25 trialsNCT07460375 2026-03-10
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Not yet recruiting
NCT07346846 2026-03-02
A Study of BGM-2121 in Patients With Advanced Solid Tumors
BioGate Precision Medicine Corp.
Phase 1 Not yet recruiting
NCT07413328 2026-02-27
HWS116 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1 Not yet recruiting
NCT07412665 2026-02-17
A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
Beijing Geekgene Technology Co., LTD
Phase EARLY_PHASE1 Not yet recruiting
NCT07380386 2026-02-02
SKB105 for Injection in Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07327294 2026-01-08
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
Evopoint Biosciences Inc.
Phase 1/2 Not yet recruiting
NCT07275853 2025-12-10
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
TCRx Therapeutics Co.Ltd
Phase 1 Not yet recruiting
NCT07222969 2025-10-30
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
Vibrant Sciences Limited
Phase 1/2 Not yet recruiting
NCT07060989 2025-07-11
NTS071
Nutshell Therapeutics (Shanghai) Co., LTD.
Phase 1/2 Not yet recruiting
NCT07061639 2025-07-11
A Study of QLS5133 Monotherapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07049458 2025-07-03
Study of CHO-A04 in Advanced Solid Tumors
Cho Pharma Inc.
Phase 1/2 Not yet recruiting
NCT06998173 2025-05-31
Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor
Danatlas Pharmaceuticals Co., Ltd
Phase 1 Not yet recruiting
NCT06976931 2025-05-16
Study on the Safe Dosage and Therapeutic Effect of the Drug YY2201 Tablets on Patients With Advanced Cancer
Jiangsu YaYao Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
NCT06963398 2025-05-09
A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06932094 2025-04-23
Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06925659 2025-04-17
A Study of QLM2011 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical (Hainan) Co., Ltd.
Phase 1 Not yet recruiting
NCT06885645 2025-04-03
First-In-Human Study in Participants With Advanced Solid Tumors
Chengdu Kanghong Biotech Co., Ltd.
Phase 1 Not yet recruiting
NCT06889675 2025-03-21
First in Human Study of YB1-X7 Injection
Shanghai Salvectors Biotechnology LTD.
Phase NA Not yet recruiting
NCT06787950 2025-01-22
Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Phase 1/2 Not yet recruiting
NCT06704828 2024-11-26
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT06598735 2024-09-19
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Not yet recruiting
NCT06474455 2024-06-25
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06026501 2023-09-07
A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1/2 Not yet recruiting
NCT05804864 2023-04-07
A Study of KM501 in Patients With Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1 Not yet recruiting